Literature DB >> 21419142

The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Shahrdad Lotfipour1, Monica M Arnold, Derk J Hogenkamp, Kelvin W Gee, James D Belluzzi, Frances M Leslie.   

Abstract

Our current study aims to evaluate the mechanisms of tranylcypromine (TCP)-mediated enhancement of nicotine self-administration. We replicated our previous findings which demonstrate that 1 h pretreatment with TCP (3 mg/kg, i.p.) enhances nicotine self-administration (7.5 μg/kg/inj, i.v.) when compared with vehicle-treated rodents. We tested whether TCP-mediated enhancement of nicotine self-administration was due to MAO inhibition or off-target effects by (i) extending the TCP pretreatment time from 1 to 20 h, and (ii) evaluating the role of the individual TCP stereoisomers in nicotine self-administration studies. While 20 h and (-)TCP pretreatment induced significant inhibition of MAO (60-90%), animals found nicotine only weakly reinforcing. Furthermore, while both (+) and (±)TCP treatment induced nearly 100% MAO inhibition, (+)TCP pretreated animals took longer to acquire nicotine self-administration compared to (±)TCP pretreated animals. Stable nicotine self-administration in (+)TCP pretreated animals was influenced by nicotinic receptor activation but not nicotine-paired cues. The opposite was found in (±)TCP pretreated animals. Treatment with (-) or (±)TCP increased dopamine and serotonin overflow, while the (+) and (±)TCP treatment enhanced monoamine overflow subsequent to nicotine. Together, our data suggests TCP enhancement of nicotine self-administration are mediated through mechanisms independent of MAO inhibition, including nicotine-paired cues and monoamine uptake inhibition.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419142      PMCID: PMC3105177          DOI: 10.1016/j.neuropharm.2011.03.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  49 in total

1.  Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats.

Authors:  Ryan F Yoshimura; Derk J Hogenkamp; Wen Y Li; Minhtam B Tran; James D Belluzzi; Edward R Whittemore; Frances M Leslie; Kelvin W Gee
Journal:  J Pharmacol Exp Ther       Date:  2007-09-14       Impact factor: 4.030

2.  Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?

Authors:  Glen B Baker; Bernard Sowa; Kathryn G Todd
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

3.  Age, sex and early environment contribute to individual differences in nicotine/acetaldehyde-induced behavioral and endocrine responses in rats.

Authors:  Minjung K Park; James D Belluzzi; Sun-Ho Han; Junran Cao; Frances M Leslie
Journal:  Pharmacol Biochem Behav       Date:  2006-12-01       Impact factor: 3.533

Review 4.  Update on pharmacologic options for smoking cessation treatment.

Authors:  Mitchell Nides
Journal:  Am J Med       Date:  2008-04       Impact factor: 4.965

5.  Prenatal nicotine exposure changes natural and drug-induced reinforcement in adolescent male rats.

Authors:  Ryan M Franke; Minjung Park; James D Belluzzi; Frances M Leslie
Journal:  Eur J Neurosci       Date:  2008-06       Impact factor: 3.386

6.  The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats.

Authors:  Thomas E Wooters; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2007-11       Impact factor: 2.293

7.  Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats.

Authors:  Leontien Diergaarde; Tommy Pattij; Ingmar Poortvliet; François Hogenboom; Wendy de Vries; Anton N M Schoffelmeer; Taco J De Vries
Journal:  Biol Psychiatry       Date:  2007-09-19       Impact factor: 13.382

8.  Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion.

Authors:  Karine Guillem; Caroline Vouillac; George F Koob; Martine Cador; Luis Stinus
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  Tranylcypromine enhancement of nicotine self-administration.

Authors:  Anne-Sophie Villégier; Shahrdad Lotfipour; Susan C McQuown; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2007-02-20       Impact factor: 5.250

10.  Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-11-14       Impact factor: 17.586

View more
  13 in total

1.  Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.

Authors:  Sarah J Cross; Daisy D Reynaga; Michelle Cano; James D Belluzzi; Nurulain T Zaveri; Frances M Leslie
Journal:  Neuropharmacology       Date:  2019-11-06       Impact factor: 5.250

Review 2.  Behavioral mechanisms underlying nicotine reinforcement.

Authors:  Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny
Journal:  Curr Top Behav Neurosci       Date:  2015

Review 3.  Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review.

Authors:  Konstantinos E Farsalinos; Riccardo Polosa
Journal:  Ther Adv Drug Saf       Date:  2014-04

4.  A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Miguel Alvarez-Estrada; Arthur L Brody
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

5.  Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence.

Authors:  Ami Cohen; George F Koob; Olivier George
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

6.  Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine.

Authors:  Tracy T Smith; Laura E Rupprecht; Samantha N Cwalina; Matthew J Onimus; Sharon E Murphy; Eric C Donny; Alan F Sved
Journal:  Neuropsychopharmacology       Date:  2016-03-09       Impact factor: 7.853

7.  Effects of MAO inhibition and a combination of minor alkaloids, β-carbolines, and acetaldehyde on nicotine self-administration in adult male rats.

Authors:  Tracy T Smith; Matthew B Schaff; Laura E Rupprecht; Rachel L Schassburger; Deanne M Buffalari; Sharon E Murphy; Alan F Sved; Eric C Donny
Journal:  Drug Alcohol Depend       Date:  2015-07-13       Impact factor: 4.492

8.  β-Carbolines found in cigarette smoke elevate intracranial self-stimulation thresholds in rats.

Authors:  Andrew C Harris; Peter Muelken; Mark G LeSage
Journal:  Pharmacol Biochem Behav       Date:  2020-09-11       Impact factor: 3.533

Review 9.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

10.  Targeted deletion of the mouse α2 nicotinic acetylcholine receptor subunit gene (Chrna2) potentiates nicotine-modulated behaviors.

Authors:  Shahrdad Lotfipour; Janet S Byun; Prescott Leach; Christie D Fowler; Niall P Murphy; Paul J Kenny; Thomas J Gould; Jim Boulter
Journal:  J Neurosci       Date:  2013-05-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.